ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
An Investigational Drug Study in Obese (Considerably Overweight) Patients

This study has been completed.

Sponsored by: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT00109148
  Purpose

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).


Condition Intervention Phase
Obesity
 Drug: MK0364
 Phase II

MedlinePlus related topics:   Obesity   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control
Official Title:   A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients

Further study details as provided by Merck:

Enrollment:   500
Study Start Date:   July 2004
Study Completion Date:   February 2005

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients who are obese (considerably overweight) based on body mass index.

Exclusion Criteria:

  • Patients with serious or unstable current or past medical conditions
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00109148

Sponsors and Collaborators
Merck

Investigators
Study Director:     Medical Monitor     Merck    
  More Information


Publications indexed to this study:
Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008 Jan;7(1):68-78.
 

Responsible Party:   Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:   2005_011, MK0364-006
First Received:   April 22, 2005
Last Updated:   July 28, 2008
ClinicalTrials.gov Identifier:   NCT00109148
Health Authority:   United States: Food and Drug Administration

Keywords provided by Merck:
Obesity and obesity-related medical conditions  

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overnutrition
Overweight

ClinicalTrials.gov processed this record on October 07, 2008

U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers